- Home
- EAF vs MOLN Comparison
EAF vs MOLN Comparison
Compare EAF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EAF | MOLN |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 170.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EAF | MOLN |
|---|---|---|
| Price | $7.13 | $4.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $11.75 | $8.38 |
| AVG Volume (30 Days) | ★ 363.7K | 1.2K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $3.53 |
| 52 Week High | $20.32 | $5.36 |
Technical Indicators
Market Signals| Indicator | EAF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.97 | 42.89 |
| Support Level | $6.20 | $4.00 |
| Resistance Level | $8.06 | $4.19 |
| Average True Range (ATR) | 0.66 | 0.07 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 44.60 | 1.47 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.